Latest & greatest articles for memantine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on memantine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on memantine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for memantine

21. Memantine Accord

Memantine Accord 19 September 2013 EMA/610378/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Memantine Accord International non-proprietary name: memantine Procedure No. EMEA/H/C/002766 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail (...) on the procedure 1.1. Submission of the dossier The applicant Accord Healthcare Limited submitted on 3 September 2012 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Memantine Accord, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004– ‘Generic of a Centrally authorised product’. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 21 June 2012. The application concerns a generic medicinal product as defined

2013 European Medicines Agency - EPARs

22. Randomised controlled trial: Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine

Randomised controlled trial: Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor (...) name or password? You are here Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Article Text Therapeutics Randomised controlled trial Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine Pierre N Tariot Statistics

2013 Evidence-Based Medicine

23. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. (Abstract)

Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. 22711111 2012 08 20 2013 04 17 1539-3704 156 12 2012 Jun 19 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. JC6-10 10.7326/0003-4819-156-12-201206190-02010 Burke David D St. Vincent's Health Network, Sydney, New South Wales, Australia. eng Comment Journal Article United States Ann Intern Med

2012 Annals of Internal Medicine

24. Memantine in Combination with Cholinesterase Inhibitors for Alzheimer?s Disease: Clinical Effectiveness and Safety

Memantine in Combination with Cholinesterase Inhibitors for Alzheimer?s Disease: Clinical Effectiveness and Safety Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time (...) for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Memantine

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

25. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease

Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease Lachaine J, Beauchemin C, Legault M, Bineau S Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of adding memantine to the usual cholinesterase inhibitor treatment for patients with Alzheimer's disease. The authors concluded that the addition of memantine was cost-effective, compared with a cholinesterase inhibitor alone. The methods were

2012 NHS Economic Evaluation Database.

26. Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands Full Text available with Trip Pro

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands Hoogveldt B, Rive B, Severens J, Maman K, Guilhaume C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of memantine, relative to standard care, for the treatment of patients with moderate-to-severe Alzheimer’s disease, from a societal perspective. The authors concluded that memantine was more effective and less expensive than usual care, in the Netherlands. The cost-effectiveness

2012 NHS Economic Evaluation Database.

27. Memantine Merz - memantine hydrochloride

Memantine Merz - memantine hydrochloride 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged. 20 September 2012 EMA/741024/2012 Committee for Medicinal Products for Human Use (CHMP) Assessment report Memantine Merz International non (...) -proprietary name: memantine Procedure No. EMEA/H/C/002568 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. Memantine Merz CHMP assessment report Page 2/8 Table of contents 1. Background information on the procedure 4 1.1. Submission of the dossier 4 1.2. Steps taken for the assessment of the product 4 2. Scientific discussion 5 2.1. Introduction 5 2.2. Non- clinical aspects 5 2.2.1. Introduction 5 2.2.2. Ecotoxicity/Environmental risk assessment

2012 European Medicines Agency - EPARs

28. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. (Abstract)

Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Prevalence of Alzheimer's disease in people with Down's syndrome is very high, and many such individuals who are older than 40 years have pathological changes characteristic of Alzheimer's disease. Evidence to support treatment with Alzheimer's drugs is inadequate, although memantine is beneficial in transgenic mice. We aimed to assess safety and efficacy (...) of memantine on cognition and function in individuals with Down's syndrome.In our prospective randomised double-blind trial, we enrolled adults (>40 years) with karyotypic or clinically diagnosed Down's syndrome, with and without dementia, at four learning disability centres in the UK and Norway. We randomly allocated participants (1:1) to receive memantine or placebo for 52 weeks by use of a computer-generated sequence and a minimisation algorithm to ensure balanced allocation for five prognostic factors

2012 Lancet Controlled trial quality: predicted high

29. Donepezil and memantine for moderate-to-severe Alzheimer's disease. Full Text available with Trip Pro

Donepezil and memantine for moderate-to-severe Alzheimer's disease. Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease.We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini (...) -Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received the study treatment for 52 weeks. The coprimary outcomes were scores on the SMMSE and on the Bristol Activities of Daily Living Scale (BADLS, on which scores range from 0 to 60, with higher scores indicating greater impairment

2012 NEJM Controlled trial quality: predicted high

30. [Responder analyses for memantine in Alzheimer's disease - Rapid report]

[Responder analyses for memantine in Alzheimer's disease - Rapid report] Responderanalysen zu memantin bei alzheimer demenz [Responder analyses for memantine in Alzheimer's disease - Rapid report] Responderanalysen zu memantin bei alzheimer demenz [Responder analyses for memantine in Alzheimer's disease - Rapid report] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation IQWiG. Responderanalysen zu memantin bei alzheimer demenz. [Responder analyses for memantine in Alzheimer's disease - Rapid report] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 84. 2011 Authors' objectives The research question of the present investigation is as follows:
What is the impact of the responder analyses calculated post hoc by Merz and submitted to the G-BA in the fourth quarter of 2010

2011 Health Technology Assessment (HTA) Database.

31. Responder analyses on memantine in Alzheimer's disease

Responder analyses on memantine in Alzheimer's disease Executive Summary IQWiG Reports – Commission No. A10-06 Responder analyses on memantine in Alzheimer’s disease 1 1 Translation of the executive summary of the rapid report “Responderanalysen zu Memantin bei Alzheimer Demenz” (Version 1.0; Status: 28.03.2011). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . Executive summary of rapid report A10-06 Responder analyses on memantine in Alzheimer’s disease 28.03.2011 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Version 1.0 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Responder analyses on memantine in Alzheimer’s disease Contracting agency: Federal Joint Committee Commission awarded on: 04.11.2010 Internal Commission No.: A10-06 Publisher’s address: Institute for Quality and Efficiency in Health

2011 Institute for Quality and Efficiency in Healthcare (IQWiG)

32. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer&#39

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer' Overview | Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance | NICE Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 Last updated: 20 June 2018 Share Save Guidance on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (NG97) and replaces NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new that affects recommendations 1.1, 1.2, 1.4, 1.5 and 1.6. Recommendation 1.3 was updated in June 2018 in NICE’s guideline on dementia (NG97

2011 National Institute for Health and Clinical Excellence - Technology Appraisals

33. Review: in people with dementia, cholinesterase inhibitors may increase syncope and memantine may reduce fractures

Review: in people with dementia, cholinesterase inhibitors may increase syncope and memantine may reduce fractures Review: in people with dementia, cholinesterase inhibitors may increase syncope and memantine may reduce fractures | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: in people with dementia, cholinesterase inhibitors may increase syncope and memantine may reduce fractures Article Text Therapeutics Review: in people

2011 Evidence-Based Mental Health

34. Memantine for patients with Parkinson`s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial (Abstract)

Memantine for patients with Parkinson`s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed. Therefore, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson's disease dementia (PDD) or dementia with Lewy (...) bodies (DLB).Patients (≥50 years of age) with mild to moderate PDD or DLB were recruited from 30 specialist centres in Austria, France, Germany, the UK, Greece, Italy, Spain, and Turkey. They were randomly assigned to placebo or memantine (20 mg per day) according to a computer-generated list. Patients and all physicians who had contact with them were masked to treatment assignment. No primary endpoint was defined. Safety analyses were done for all patients who took at least one dose of memantine

2010 EvidenceUpdates Controlled trial quality: predicted high

35. Namenda XR (memantine hydrochloride) extended release capsules

Namenda XR (memantine hydrochloride) extended release capsules Drug Approval Package: Namenda XR (memantine) NDA #022525 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Namenda XR (memantine hydrochloride) 7 mg, 14 mg, 21 mg, & 28 mg extended release capsules Company: Forest Laboratories, Inc. Application No.: 022525 Approval Date: 6/21/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance

2010 FDA - Drug Approval Package

36. Memantine pump device (Ebixa): risk of medication errors

Memantine pump device (Ebixa): risk of medication errors Memantine pump device (Ebixa): risk of medication errors - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Memantine pump device (Ebixa): risk of medication errors Differences in dose delivery between the pump device and dropper device for memantine. Published 11 December 2014 From: Therapeutic area: , Contents Article date: November 2010 Memantine (Ebixa) is indicated for the treatment of patients with moderate to severe (...) Alzheimer’s disease, and tablets and an oral solution have been available since 2002. A pump device was introduced in March 2010 and replaces memantine oral solution administered by a dropper, which is being phased out by February 2011. Risk of medication errors and accidental overdose Up to 9 August 2010, 7 cases of administration errors with the pump device have been reported worldwide. One patient was admitted to hospital and recovered, and 2 patients experienced somnolence, which is listed

2010 MHRA Drug Safety Update

37. Cost effectiveness of memantine in Alzheimer's disease in the UK Full Text available with Trip Pro

Cost effectiveness of memantine in Alzheimer's disease in the UK Cost effectiveness of memantine in Alzheimer's disease in the UK Cost effectiveness of memantine in Alzheimer's disease in the UK Rive B, Grishchenko M, Guilhaume-Goulant C, Katona C, Livingston G, Lamure M, Toumi M, Francois C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study objective was to assess the cost-effectiveness of memantine for treatment of moderate to severe Alzheimer’s disease. The authors concluded that memantine could be regarded as a cost-effective treatment. The study methodology was good and the methods and results were reported adequately. Given the scope of the study, the authors’ conclusions appear valid. Type of economic

2010 NHS Economic Evaluation Database.

38. Memantine in patients with Parkinson`s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial (Abstract)

Memantine in patients with Parkinson`s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms of dementia that substantially affect quality of life. Currently, the only treatment licensed for PDD is rivastigmine, and there are no licensed treatments for DLB. We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine (...) in patients with PDD or DLB.We did a parallel-group, 24-week, randomised controlled study of memantine (20 mg per day) versus placebo at four psychiatric and neurological outpatient clinics in Norway, Sweden, and the UK during 2005-08. Patients were included if they fulfilled the UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria for Parkinson's disease (PD) and developed dementia according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM IV) criteria

2009 EvidenceUpdates Controlled trial quality: predicted high

39. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia (Abstract)

Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia We conducted a randomized, double-blind, placebo-controlled, parallel-group study of both memantine and constraint-induced aphasia therapy (CIAT) on chronic poststroke aphasia followed by an open-label extension phase.Patients were randomized to memantine (20 mg/day) or placebo alone during 16 weeks, followed by combined drug treatment with CIAT (weeks 16-18), drug treatment alone (weeks 18-20), and washout (weeks 20 (...) -24), and finally, an open-label extension phase of memantine (weeks 24-48). After baseline evaluations, clinical assessments were done at two end points (weeks 16 and 18), and at weeks 20, 24, and 48. Outcome measures were changes in the Western Aphasia Battery-Aphasia Quotient and the Communicative Activity Log.Twenty-eight patients were included, and 27 completed both treatment phases. The memantine group showed significantly better improvement on Western Aphasia Battery-Aphasia Quotient

2009 EvidenceUpdates Controlled trial quality: predicted high

40. Memantine for dementia in people with Down syndrome. Full Text available with Trip Pro

Memantine for dementia in people with Down syndrome. Alzheimer's dementia (AD) is the most common form of dementia in people with Down Syndrome (DS). There is an understanding that an increase in L-glutamate contributes to the pathogenesis of cerebral ischemias and AD. Memantine acts as an antagonist of N-methyl-D-aspartate (NMDA) type receptors, which is thought to reduce abnormal activation of glutamate neurotransmission. It binds with a low affinity to the NMDA receptor and so should (...) not prevent learning and the formation of memory. Memantine can improve cognitive function and slow the decline of AD in the general population over time, and is the subject of this review. It is important to note that people with DS tend to present with AD at a much younger age than the normal population as well as having subtle differences in physiology (e.g. metabolism and heart rate) and may therefore have different requirements from the general population.To determine the effectiveness and safety

2009 Cochrane